PROGRESSIVE PULMONARY FIBROSIS

This study aims to check the long-term safety and side effects of an inhaled medication for people with progressive lung scarring (pulmonary fibrosis). It is open to people who have already completed a previous study with this type of inhaled drug. Participants will use the medic…

This large, late-stage study is testing whether an inhaled medication called treprostinil can safely slow the progression of lung scarring (progressive pulmonary fibrosis) in adults. About 700 participants will use either the drug or a placebo inhaler four times a day for one yea…

This study is testing whether an inhaled version of a medication called pirfenidone (AP01) can slow the progression of progressive pulmonary fibrosis (PPF), a serious lung scarring disease. About 375 participants will be randomly assigned to receive either a high dose, a low dose…

This study is testing whether a natural supplement called quercetin can help control progressive lung scarring (fibrosis) in people with certain lung diseases. One hundred patients will be randomly assigned to take either quercetin plus their standard care or just standard care a…

This study is testing a new, more efficient way for patients with chronic lung scarring diseases (like pulmonary fibrosis) to attend their regular hospital check-ups. Currently, these visits can be spread over multiple days, requiring separate trips for tests and doctor appointme…

This study is for people with progressive lung scarring diseases who previously took BI 1015550 in another trial. Researchers want to see how well people tolerate this medication long-term and whether it helps preserve lung function and delay serious health events. Participants t…

This study is testing a mobile app called SUPPORT-T to see if it's a practical and helpful way to deliver supportive care to people with progressive pulmonary fibrosis (a scarring lung disease) and their caregivers. The app provides a 9-week guided program and virtual support gro…

This study aims to understand how anti-fibrotic medications for lung fibrosis affect patients' body composition—specifically fat and muscle—which regular weight checks might miss. Researchers will use quick, non-invasive scans (bioimpedance analysis and muscle ultrasound) on 30 p…

This study aims to better understand and predict how certain lung scarring diseases get worse over time. Researchers will follow 500 adults with specific types of lung scarring for two years, collecting health data and blood samples. The goal is to improve how doctors classify an…